TransMedics Group, Inc. (TMDX) experienced a significant plummet of 8.62% in its stock price during the pre-market session on Monday, January 13th, 2025.
The company issued a statement in response to what they believe are "inaccurate and misleading claims" made in a short-seller report published by Scorpion Capital on January 10th, 2025. TransMedics strongly denied the allegations and stated that the report failed to accurately represent the company's business, technology, diverse culture, and focus on delivering exceptional products and services to the global transplant community.
TransMedics stood by the integrity of its practices, compliance with applicable laws, and commitment to improving clinical outcomes in organ transplantation. The company highlighted that its Organ Care System (OCS) technology and National OCS Program (NOP) have enabled over 7,000 organ transplants, expanded overall U.S. transplant volumes, and delivered exceptional post-transplant clinical outcomes for patients, as validated by their extensive clinical data set.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。